Objectives-To date, quantitation of TAFI antigen levels has been mainly focused on "total" antigen levels and has been shown to yield ambiguous results because of the existence of different isoforms and various degrees of activation. Our objective was to develop assays that allow measuring the extent of TAFI activation. Methods and Results-A variety of enzyme-linked immunosorbent assays (ELISAs) were evaluated for their preferential reactivity toward TAFI before and after activation, and toward the recombinantly expressed activation peptide. Three ELISAs with distinct reactivities were selected: recognizing either exclusively nonactivated TAFI, the released activation peptide, or exclusively TAFIa (activated TAFI). Evaluation of TAFI activation during clot lysis revealed that decreases of TAFI levels are associated with increases of the released activation peptide and TAFIa levels. In addition, antigenic measurement of TAFIa parallels activity measured by chromogenic assay. Analyzing plasma samples revealed that subjects with hyperlipidemia had significantly higher plasma levels of both the activation peptide (109.2 versus 95.5; PϽ0.001) and TAFIa (112.1 versus 103.3; Pϭ0.03), and not of TAFI antigen (92.5 versus 87.9; Pϭ0.07) (results in % of plasma pooled from normolipidemic subjects). Conclusion-ELISAs that allow to measure the extent of TAFI activation were developed. These ELISAs constitute more sensitive markers in studies on the relationship between TAFI and cardiovascular diseases. (Arterioscler Thromb Vasc Biol. 2006;26:423-428.)
T he proenzyme thrombin activatable fibrinolysis inhibitor (TAFI; procarboxypeptidase U [proCPU]) can be activated to the active enzyme (TAFIa; carboxypeptidase U [CPU]) by trypsin-like enzymes such as thrombin, plasmin, or the thrombin/thrombomodulin complex (T/TM). [1] [2] [3] On activation of TAFI (Phe 1 -Val 401 ; 56 kDa), the activation peptide (AP) (Phe 1 -Arg 92 ; 20 kDa, 4 N-linked glycosylations 4 ) is released from the catalytic domain (TAFIa, Ala 93 -Val 401 ; 36 kDa). Subsequently, TAFIa is inactivated through a conformational change to an inactive form (TAFIai), followed by proteolytic cleavage resulting in fragments of 25 and 11 kDa. 5 TAFIa exerts an antifibrinolytic effect by removing C-terminal lysine residues from fibrin, resulting in a decreased plasmin formation and a retardation of clot lysis. 6 TAFIa is highly unstable in vitro (half-life at 37°C between 8 to 15 minutes). [7] [8] [9] [10] Different clinical studies have investigated the possible relationship between TAFI and cardiovascular events. A positive correlation was found between TAFI levels and the risk for coronary artery disease, 11 venous thrombosis, 12 angina pectoris, 13 and ischemic stroke. 14 However, another study revealed that elevated TAFI may be protective against myocardial infarction. 15 A possible explanation for these contradictory results was that the different studies used different methods for TAFI determination. 16 14 Malyszko et al found that elevated TAFI (Actichrome TAFIa; American Diagnostica) might be a link in the pathogenesis of impaired fibrinolysis in diabetic nephropathy and thus atherosclerosis progression. 17 Saibeni et al found that increased TAFI levels (enzyme-linked immunosorbent assay [ELISA]; Affinity Biologicals) might contribute to the prothrombotic state observed in inflammatory bowel syndrome through the induction of hypofibrinolysis. 18 Eichinger et al showed that patients with higher TAFI levels (ELISA; American Diagnostica) have a higher risk for recurrent venous thromboembolism. 19 To date, quantitation of TAFI antigen levels, as a putative risk marker for cardiovascular events, has been mainly focused on "total" antigen levels (either by ELISA or by activity assays after full activation of TAFI), reporting levels of 4 to 15 g/mL. 16,20 -22 However, it should be stressed that in most of these studies the used immunologic assays were not validated with respect to putative differential reactivities toward different isoforms and fragments of TAFI. Therefore, it cannot be excluded that apparently increased or decreased TAFI levels associated with particular disease states is not caused by differences in total TAFI protein levels but rather to differences in isoforms or differences in extent of activation. In this respect, it is important to note that recent studies, 23, 24 revealing a threshold phenomenon, have suggested that not the total amount of TAFI protein, but the amount of activated TAFI may play a critical role in the interference with fibrinolysis. Therefore, and because of the complications in the use of activity assays, we hypothesized that immunologic measurement of the extent of TAFI activation (ie, either by measuring the released activation peptide or by measuring TAFIa) could represent a more relevant parameter.
In this study, we screened a variety (Ͼ1500) of monoclonal antibody (MA)-based ELISAs for their preferential reactivity toward TAFI before and after activation and toward the recombinantly expressed AP. This allowed us to select 3 ELISAs with distinct properties, recognizing either exclusively nonactivated TAFI, the released AP, or exclusively TAFIa.
Methods
Please see http://atvb.ahajournals.org for detailed Methods.
Results

Construction, Selection, and Characterization of Sandwich-Type ELISAs for Detection of Different TAFI Fragments
Forty monoclonal antibodies were pair-wise tested for their reactivity toward pTAFI before and after activation. Two groups of ELISAs could be distinguished: one group reacts only with intact, nonactivated TAFI and a second group reacts only with TAFI after it has been activated. Within this second group, 2 subgroups were identified: one subgroup reacted with the recombinant AP, whereas the other subgroup did not. Based on these preferential reactivities toward different TAFI fragments, 3 ELISA combinations were se-lected for further characterization: MA-T12D11/MA-T30E5-HRP, reacting with nonactivated TAFI, MA-T12D11/MA-T18A8-HRP, reacting with TAFI after activation as well as with the recombinant AP, and MA-T30E5/MA-T17D7-HRP, reacting with TAFI after activation but not with the recombinant AP.
Preliminary experiments, using Western blotting (data not shown), indicated that the epitopes of MA-T12D11 and MA-T18A8 reside in the region of the AP, whereas for MA-T17D7 the epitope resides in the 36-kDa fragment. Because MA-T30E5 does not work in blotting experiments, no information on the binding region is available.
For calibration of the selected ELISAs, 2 standards were developed, ie, S 0 and S 10 (cfr methods). The response of S 10 in the MA-T12D11/MA-T30E5-HRP ELISA was 11Ϯ3.2% compared with S 0 , whereas the response of S 0 in the MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-T17D7-HRP ELISA was 0.7Ϯ0.6% and 4.0Ϯ2.1% compared with S 10 , respectively. Only MA-T12D11/MA-T18A8-HRP reacted with the recombinant AP: 100 g/mL recombinant AP gave a response of 101Ϯ11% compared with S 10 . Typical standard curves of the three ELISAs are shown in Figure 1 .
TAFI fragments formed on activation of pTAFI with T/TM are shown in the inset of Figure 2A . At 5 minutes, the 56-kDa fragment of TAFI is completely converted to the 36-kDa fragment. Subsequently, at 10 minutes, the degradation products of 25 and 11 kDa are formed and eventually, and after 30 minutes, the 36 kDa fragment is completely degraded. The activation peptide of TAFI has a theoretical Mr of 19.4 kDa (with carbohydrate). In agreement with the literature, no distinct activation peptide after activation of TAFI was detected using SDS-PAGE and silver staining. 10, 25, 26 However, Guimaraes et al showed, using SDS-PAGE and Western blotting, that the released activation peptide co-migrates as a 33-kDa broadband with the 36 kDa catalytic domain of TAFI. 27 TAFIa activity, generated on activation of pTAFI with T/TM (Figure 2A ), reaches a maximum at 5 minutes and then decreases, reaching a minimum at 20 minutes, in agreement with the appearance and the disappearance of the 36-kDa fragment. The response of pTAFI ( Figure 2A ) in MA-T12D11/MA-T30E5-HRP decreases on activation, reaching a minimum after 5 minutes (Ͻ2%, 47Ϯ15-fold decrease, PϽ0.0001 versus tϭ0 minutes). In contrast, the response in MA-T12D11/MA-T18A8-HRP increases in function of time . Y-axis represents the OD at 430 nm and X-axis represents the different plasma dilutions ranging from 1:2560 to 1:40 (of which 1:320, 1:160, 1:80, and 1:40 dilutions are indicated). (▫) represents the reactivity of recombinant AP applied at a concentration equimolar to that in plasma (ie, 10 g/mL TAFI contains 3.57 g/mL AP). The 1/40 dilution of the standards corresponds with 90 ng/mL rAP.
reaching a maximum at 5 minutes, which is maintained to 20 minutes (74Ϯ26-fold increase, PϽ0.0001 versus tϭ0 minutes), followed by a slow decrease. The response in MA-T30E5/MA-T17D7-HRP increases on activation reaching a maximum at 5 minutes (70Ϯ10-fold increase, PϽ0.0001 versus tϭ0 minutes) and then decreases reaching a minimum after 60 minutes (Ͻ2%). Similar results were obtained using plasmin to activate TAFI (data not shown) and using 2 recombinant TAFI isoforms (ie, TAFI-Ala 147 Thr 325 and TAFI-Ala 147 Ile 325 ) (see http://atvb.ahajournals.org). The response in MA-T30E5/MA-T17D7-HRP decreased after reaching a maximum with a half-life of 14.0Ϯ0.2 minutes for TAFI-Ala 147 Thr 325 versus 15.9Ϯ0.3 minutes for TAFI-Ala 147 Ile 325 (PϽ0.05), respectively, in line with the increased stability of TAFIa of the Ile 325 isoform. 8 TAFIa activity in plasma ( Figure 2B ) reaches a maximum after 10 minutes and then decreases, reaching a minimum after 30 minutes. The response of pooled human plasma ( Figure 2B ) in MA-T12D11/MA-T30E5-HRP decreases on activation, reaching a minimum after 30 minutes (Ͻ15%, 7.6Ϯ2.6-fold decrease, PϽ0.0001 versus tϭ0 minutes). In contrast, the response in MA-T12D11/MA-T18A8-HRP increases on activation reaching a maximum plateau after 30 minutes (60Ϯ18-fold increase, PϽ0.0001 versus tϭ0 minutes). The response in MA-T30E5/MA-T17D7-HRP increases on activation reaching a maximum after 10 minutes (24Ϯ14-fold increase, Pϭ0.002 versus tϭ0 minutes), immediately followed by a decrease, reaching a minimum after 60 to 120 minutes (Ͻ25%).
Taken together, all aforementioned results demonstrate that MA-T12D11/MA-T30E5-HRP preferentially reacts with intact nonactivated TAFI, MA-T12D11/MA-T18A8-HRP reacts with the released AP and MA-T30E5-T17D7-HRP reacts with TAFIa and/or TAFIai.
Quantitation of TAFI in Plasma
A linear dose-response curve was observed in all 3 ELISAs when plasma (either nonactivated for the MA-T12D11/MA-T30E5-HRP ELISA or activated for the MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-T17D7-HRP ELISA) was diluted between 1/40-fold and 1/2560-fold. Within the linear portion of these curves, correlation coefficients exceeded 0.98.
For recoveries, intra-assay, inter-assay, and interdilution coefficients of variation and detection limits of the 3 ELISAs (please see http://atvb.ahajournals.org).
Application of the Developed Assays In Vitro and In Vivo
During clot formation and dissolution, TAFIa activity was measured using the chromogenic assay and antigen levels of TAFI and TAFI fragments were followed using the 3 described ELISAs (Figure 3 ).
As reported before, 28 a biphasic pattern of TAFIa activity generation during in vitro clot lysis was observed. A first TAFIa activity peak was found immediately after clot formation, and a second peak during clot dissolution. Our data show that in the presence of 0.5 nM TM ( Figure 3A ), TAFI antigen levels (measured with MA-T12D11/MA-T30E5- HRP) decreased, whereas released AP antigen levels (measured with MA-T12D11/MA-T18A8-HRP) increased concomitantly, both in a similar biphasic pattern. Antigen levels of TAFIa/ai (measured with MA-T30E5/MA-T17D7-HRP) increased during clot formation, followed by a decrease and increased slightly during clot dissolution, followed by a decrease. Under these conditions, TAFI antigen levels decreased, in a biphasic pattern, to 83Ϯ16% after clot formation and to 49Ϯ8.6% after clot dissolution; the released AP levels increased, in a biphasic pattern, to 25Ϯ1.7% after clot formation and to 47Ϯ5.3% after clot dissolution. TAFIa/ai antigen levels increased to 27Ϯ3.5% during clot formation and to 7.3Ϯ0.3% during dissolution. Strikingly, the biphasic changes as observed in the ELISAs coincide with the biphasic pattern observed in the TAFIa activity assay.
As reported before, 28 higher TM concentrations (Figure 3A versus Figure 3B ) increased the height and width of the first activity peak. With 5 nM TM ( Figure 3B ), the biphasic pattern was not observed. TAFI antigen levels immediately decreased to 3.2Ϯ1.2% after clot formation, released activation peptide antigen levels immediately increased to 108Ϯ15.2% after clot formation. TAFIa/ai antigen levels increased transiently to 79Ϯ3.7% during clot formation. Again, these data demonstrate the differential reactivities of the ELISAs and their respective association with the activity assay. A decrease of intact TAFI antigen levels is associated with an increase in released AP antigen levels and with a transient increase of TAFIa/ai antigen levels.
The in vivo clearance of the released AP and TAFIa/ai was determined in female Balb/c mice using MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-T17D7-HRP, respectively. The biological half-lives of the released AP and TAFIa/ai were 27Ϯ5.4 and 11Ϯ3.9 minutes, respectively.
Plasma samples of 13 healthy individuals were analyzed in the different ELISAs, before and after 10 minutes of activation with T/TM (cfr chromogenic assay) (http://atvb. ahajournals.org).
Quantitation of TAFI and TAFI Fragments in a Swedish Study Population
Characteristics of the study population (nϭ300) are given in Methods and Materials (http://atvb.ahajournals.org). The plasma levels of TAFI and the released AP and TAFIa were 92.1% (median; interquartilesϭ78.8% to 103.2%), 106.5% (median; interquartilesϭ93.0% to 118.2%), and 110.9% (median; interquartilesϭ96.9% to 132.1%), respectively. TAFI and TAFI fragments (TAFI variables) did not show a significant correlation to age and there were no significant gender differences except a lower plasma level of the activation peptide in men compared with women (103.8% versus 110.7%, Pϭ0.01). A significant correlation was observed between the activation peptide and intact TAFI (rϭ0.39, PϽ0.001), between TAFIa and the activation peptide (rϭ0.19, Pϭ0.001), but not between TAFIa and intact TAFI. Strikingly, intact TAFI, TAFIa, and the activation peptide showed significant correlations to cholesterol (ie, rϭ0. 15, PϽ0.05; rϭ0.12, PϽ0.05 and rϭ0.27, PϽ0 .001, respectively) and triglycerides (ie, rϭ0.14, PϽ0.05; rϭ0.14,  PϽ0.05; and rϭ0.23, PϽ0.001, respectively) , whereas no significant associations were detected for high-density lipoprotein, insulin, blood pressure, or body mass index, with the exception for a correlation between the activation peptide and body mass index (rϭ0.13, Pϭ0.03). Subjects with hyperlipidemia had significantly higher plasma levels of both the activation peptide (109.2 versus 95.5; PϽ0.001) and TAFIa (112.1 versus 103.3; Pϭ0.03), whereas the difference for intact TAFI antigen did not reach the conventional level of statistical significance (92.5 versus 87.9; Pϭ0.07). Twenty-eight subjects were on lipid-lowering therapy. If they were excluded from the analysis, similar correlations between the 3 TAFI variables and cholesterol as well as triglycerides were observed, and differences between subjects with hyperlipidemia and normolipidemia remained (activation peptide 109.9 versus 95.5, PϽ0.001; TAFIa 115.0 versus 103.3, Pϭ0.01; intact TAFI 92.6 versus 87.9, Pϭ0.03). There were no significant differences for any TAFI variable with regard to hypertension, diabetes, or smoking status (PϾ0.2 throughout). The activation peptide showed significant correlations to tissue-type plasminogen activator antigen (rϭ0.17, PϽ0.01), plasminogen activator inhibitor-1 (rϭ0.19, PϽ0.01), and fibrinogen (rϭ0.18, PϽ0.01), and an inverse correlation to tissue-type plasminogen activator activity (rϭϪ0.17, PϽ0.01), whereas intact TAFI and TAFIa revealed no significant correlation.
Discussion
TAFIa is formed on activation of TAFI with T/TM or plasmin by release of the activation peptide and exerts an antifibrinolytic effect. Two polymorphisms (ie, Ala147Thr and Thr325Ile), resulting in the existence of 4 different isoforms, have been described. 29, 30 It has been suggested that increased TAFI plasma levels or increased activation is associated with cardiovascular events such as thrombosis, angina pectoris, and myocardial infarction. [11] [12] [13] [14] [15] Therefore, different clinical studies have aimed to investigate the relationship between TAFI and cardiovascular events, based on the determination of TAFI levels in plasma. TAFI levels are determined either by immunologic assays, presumed to measure "total" TAFI antigen but not characterized in detail, or by activation of the zymogen followed by determination of total enzymatic activity reflecting total activatable TAFI levels. [11] [12] [13] [14] [15] Alternatively, clot lysis experiments 31 or the use of fluorescently labeled plasminogen 32 may also be used to quantitate TAFI levels or TAFIa activity, respectively. Apart from a previous study 16 demonstrating that the reactivity of a majority of available assays is partially dependent on the Thr 325 polymorphism, it should be realized that interpretation of TAFI antigen levels as determined with noncharacterized immunologic assays is also quite ambiguous because TAFI can occur in different forms (TAFI, TAFIa, TAFIai, fragmentation products of TAFIai, released AP). Therefore, there is currently a strong need for well-characterized immunoassays for the evaluation of the levels of different TAFI forms. In addition, immunologic measurement of the extent of TAFI activation, either by measurement of the released AP or by measurement of TAFIa (ie, TAFIa and/or TAFIai), could be a more relevant parameter. Therefore, our objective was to develop well-characterized assays that allow measurement of the extent of TAFI activation.
In this study, a panel of sandwich-type ELISAs was screened for their reactivity toward TAFI before and after activation. Three types of ELISAs could be distinguished. From the group of ELISAs, exclusively reacting with intact nonactivated TAFI, MA-T12D11/MA-T30E5-HRP was selected for further characterization. The response of purified TAFI or human plasma in MA-T12D11/MA-T30E5-HRP immediately decreases on activation, reaching a minimum at a time point corresponding with the time of exhaustion of activatable TAFI ( Figure 2B ). Taking all evidence together, including Western blotting experiments (data not shown), it can be concluded that this particular ELISA specifically reacts with intact, nonactivated TAFI.
From the group of ELISAs reacting with TAFIa, 2 ELISAs were selected, ie, MA-T12D11/MA-T18A8-HRP and MA-T30E5/MA-T17D7-HRP. These ELISAs reacted differentially on activation of TAFI (in plasma or purified). The response in MA-T12D11/MA-T18A8-HRP increases reaching a maximum plateau whereas the increased response on activation in the MA-T30E5/MA-T17D7-HRP is immediately followed by a strong decrease ( Figure 2 ). This reveals that these 2 ELISAs reacted with different fragments from TAFI. To explore this ambiguity, we cloned, expressed, and purified the AP of human TAFI. This recombinant AP reacted only in MA-T12D11/MA-T18A8-HRP, although with a much lower reactivity compared with activated TAFI. The response of purified TAFI or human plasma in MA-T12D11/ MA-T18A8-HRP increases on activation, reaching a maximum plateau value at a time-point corresponding with the time of exhaustion of activatable TAFI. All these data demonstrate that MA-T12D11/MA-T18A8-HRP specifically reacts with the released AP from TAFI. It should be mentioned that in contrast to purified TAFI, the response observed for plasma on activation remained stable after reaching the maximum. This is most likely caused by stabilization of the released AP in a plasma environment. This was confirmed by the observation that the response of activated pTAFI added to TAFI-depleted plasma remained stable (data not shown).
The response of human plasma ( Figure 2B ) in MA-T30E5/ MA-T17D7-HRP increases transiently on activation, reaching a maximum after 10 minutes. Because the response decreases after reaching the maximum, we can conclude that this ELISA reacts with the 36-kDa fragment of TAFI and not with the 25-kDA and 11-kDa products. Strikingly, the increase in MA-T30E5/MA-T17D7-HRP occurs parallel with the increase in TAFIa enzymatic activity. The delay of the decreasing response in the ELISA compared with the decrease in enzymatic activity strongly indicates that MA-T30E5/MA-T17D7-HRP reacts with both TAFIa and TAFIai. This is also confirmed by the analysis of the fragmentation products by SDS-PAGE illustrating that the reactivity in the ELISA is associated with the presence of the 36-kDa fragment and decreases concomitantly with the appearance of the 25-kDa and 11-kDa products. Analysis of 2 recombinant isoforms (ie, TAFI-Ala 147 Thr 325 and TAFI-Ala 147 Ile 325 ) revealed similar responses in the 3 ELISAs. However, the response of the Ile 325 isoform decreased significantly slower in the MA-T30E5/MA-T17D7-HRP ELISA. This is in agreement with the increased stability of Ile 325 isoforms at 37°C. 8 When using plasmin to activate TAFI, a similar response was observed except that the response in the MA-T30E5/ MA-T17D7-HRP ELISA paralleled the time course of the generation and loss of TAFIa activity (data not shown). This is in agreement with Marx et al 5 describing that on plasminmediated activation of TAFI, the appearance and disappearance of the 36-kDa fragment (ie, TAFIa/ai, followed by SDS-PAGE) matched the time course of generation and loss of TAFIa activity. This provides further evidence that the MA-T30E5/MA-T17D7-HRP ELISA reacts with both TAFIa and TAFIai.
The 3 characterized ELISAs were also used to follow the antigen levels of TAFI and TAFI fragments during clot formation and clot dissolution. When using 5 nM TM, TAFI is completely activated during clot formation, whereas in the presence of 0.5 nM TM, there is partial activation during clotting followed by subsequent activation during fibrinolysis (Figure 3 ). This is also reflected by the antigen levels of the released AP and TAFIa. With 5 nM TM, released AP levels immediately increase to 100% and TAFIa levels transiently to 80%, whereas with 0.5 nM TM the released AP increases partially during clot formation and subsequently during clot lysis. In the presence of 0.5 nM TM, the antigen levels of TAFIa follow the pattern of TAFIa activity with a first peak during clot formation and a second lower peak during clot lysis. These results are in agreement with the biphasic pattern of TAFIa generation during in vitro clot lysis in human plasma as described by Leurs et al. 28 Leurs et al also found a thrombomodulin-dependent increase of the first activity peak during clot formation, which is also confirmed by our data (Figure 3 ). 23 Analysis of 300 plasma samples revealed correlations between cholesterol and triglycerides for TAFI as well as TAFIa and AP. These findings are in agreement with the data of Silveira et al, who reported statistical correlations between TAFI and cholesterol contents of plasma and all lipoprotein fractions but high-density lipoprotein and a tendency of TAFI to correlate with the triglyceride contents of all lipoprotein fractions in healthy subjects. 11 In the current study, higher plasma levels of both the activation peptide and TAFIa were observed for subjects with hyperlipidemia, compared with subjects with normolipidemia. In contrast, no association between total TAFI antigen levels and hyperlipidemia could be observed. This suggests that there is an increased activation state in hyperlipidemia. These findings provide evidence that indeed measurement of the extent of activation is a more relevant parameter in the search for an association between TAFI levels and risk markers for cardiovascular diseases. Moreover, evidence that measuring the extent of TAFI activation is more relevant is supported by the threshold phenomenon stating that it is not the total amount of TAFI protein but the amount of TAFIa that plays a critical role in fibrinolysis. 23 The use of this kind of ELISA in large epidemiological studies might refute the contradictory results observed previously. [11] [12] [13] [14] [15] Measuring the released activation peptide (MA-T12D11/MA-T18A8-HRP ELISA), indepen-dent of intrinsic stability of TAFIa and also exhibiting the strongest correlation with hyperlipidemia, is the preferred assay.
In conclusion, we described the development of 3 different MA-based ELISAs. The MA-T12D11/MA-T30E5-HRP specifically reacts with nonactivated TAFI, the MA-T12D11/ MA-T18A8-HRP specifically reacts with the released activation peptide of TAFI and the MA-T30E5/MA-T17D7-HRP specifically reacts with TAFIa and TAFIai. Application in various settings (clot lysis, activation of plasma, clinical samples) has demonstrated that the 2 latter assays reliably provide a measure for the extent of TAFI activation and that the released activation peptide is strongly associated with hyperlipidemia.
